CCN5/WISP2 and metabolic diseases
Grünberg, John Rajan
Journal of Cell Communication and Signaling
MetadataShow full item record
Grünberg, J. R., Elvin, J., Paul, A., Hedjazifar, S., Hammarstedt, A., & Smith, U. CCN5/WISP2 and metabolic diseases. Journal of Cell Communication and Signaling https://doi.org/10.1007/s12079-017-0437-z
This is the final version of the article. It first appeared from Springer via https://doi.org/10.1007/s12079-017-0437-z
Obesity and type 2 diabetes increase worldwide at an epidemic rate. It is expected that by the year 2030 around 500 million people will have diabetes; predominantly type 2 diabetes. The CCN family of proteins has become of interest in both metabolic and other common human diseases because of their effects on mesenchymal stem cell (MSCs) proliferation and differentiation as well as being important regulators of fibrosis. We here review current knowledge of the WNT1 inducible signaling pathway protein 2 (CCN5/WISP2). It has been shown to be an important regulator of both these processes through effects on both the canonical WNT and the TGFβ pathways. It is also under normal regulation by the adipogenic commitment factor BMP4, in contrast to conventional canonical WNT ligands, and allows MSCs to undergo normal adipose cell differentiation. CCN5/WISP2 is highly expressed in, and secreted by, MSCs and is an important regulator of MSCs growth. In a transgenic mouse model overexpressing CCN5/WISP2 in the adipose tissue, we have shown that it is secreted and circulating in the blood, the mice develop hypercellular white and brown adipose tissue, have increased lean body mass and enlarged hypercellular hearts. Obese transgenic mice had improved insulin sensitivity. Interestingly, the anti-fibrotic effect of CCN5/WISP2 is protective against heart failure by inhibition of the TGFβ pathway. Understanding how CCN5/WISP2 is regulated and signals is important and may be useful for developing new treatment strategies in obesity and metabolic diseases and it can also be a target in regenerative medicine.
Adipose tissue, Fibrosis, Insulin Resistance, Metabolism, Mesenchymal stem cells, WNTsignaling
The studies in the authors’ laboratory are supported by grants from the People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme (FP7/2007-2013) under REA grant agreement (n° 608765), Henning and Johan Throne- Holst’s foundation for the promotion of scientific research, the Medical Research Council, Torsten Söderberg Foundation, Novo Nordisk Foundation, EFSD, Swedish Diabetes Foundation, Swedish ALF funds, Edgar Sjölund Foundation, Wilhelm and Martina Lundgren’s Foundation, the Magnus Bergvall Foundation, Lisa and Johan Grönberg Foundation, Göteborgs Diabetesförening, Sigurd and Elsa Golje’s Foundation, and the EU’s FP7 program (n°607842).
External DOI: https://doi.org/10.1007/s12079-017-0437-z
This record's URL: https://www.repository.cam.ac.uk/handle/1810/269791
Attribution 4.0 International
Licence URL: http://creativecommons.org/licenses/by/4.0/